Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 2883.1.

https://doi.org/10.1182/blood-2024-201478

Published: 2024

Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Philippe Moreau, MDPhD, Albert Oriol, MD, Jonathan L. Kaufman, MD, Heather Sutherland, MD, Marc Lalancette, MD FRCP, Hila Magen, MD, Shinsuke Iida, MD PhD, Jin Seok Kim, MD PhD, Miles Prince, MD FRACP, FRCPA, Tara Cochrane, Lisa O'Rourke, MSN, RN, Kaida Wu, Jordan M. Schecter, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1883.

https://doi.org/10.1182/blood.V130.Suppl_1.1883.1883

Published: 2017

Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

Meletios A. Dimopoulos, Darrell J. White, MD, Lofti Benboubker, MD, Gordon Cook, MD PhD, Merav Leiba, James Morton, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Kihyun Kim, Naoki Takezako, MD PhD, Sonali Trivedi, Kaida Wu, Tineke Casneuf, Christopher Chiu, Jordan Schecter, Philippe Moreau, MDPhD

Blood (2017) 130 (Supplement 1): 739.

https://doi.org/10.1182/blood.V130.Suppl_1.739.739

Published: 2017

Journal Articles

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study

Sagar Lonial, MD, Jesus F. San-Miguel, MD, Joaquín Martínez-Lopez, Maria-Victoria Mateos, MD, Joan Blade, Lotfi Benboubker, MD, Albert Oriol, MD, Bertrand Arnulf, Ajai Chari, Luis Pineiro, Kaida Wu, Jianping Wang, Parul Doshi, Jordan Schecter, Philippe Moreau, MDPhD

Blood (2017) 130 (Supplement 1): 1869.

https://doi.org/10.1182/blood.V130.Suppl_1.1869.1869

Published: 2017

Journal Articles

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Ajai Chari, Saad Z Usmani, MD, Amrita Krishnan, MD, Sagar Lonial, MD, Raymond Comenzo, Kaida Wu, Jianping Wang, Parul Doshi, Brendan M Weiss, MD, Jordan Schecter, Andrzej J. Jakubowiak, MD

Blood (2017) 130 (Supplement 1): 3110.

https://doi.org/10.1182/blood.V130.Suppl_1.3110.3110

Published: 2017

Journal Articles

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Thierry Facon, Sagar Lonial, MD, Brendan M Weiss, MD, Attaya Suvannasankha, MD, Joseph Fay, Bertrand Arnulf, Jainulabdeen J Ifthikharuddin, Carla de Boer, Jianping Wang, Kaida Wu, Ajai Chari, Suzanne Lentzsch, Jordan Schecter, Amrita Krishnan, MD

Blood (2017) 130 (Supplement 1): 1824.

https://doi.org/10.1182/blood.V130.Suppl_1.1824.1824

Published: 2017

Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Saad Z Usmani, MD FACP, Meletios A Dimopoulos, Andrew Belch, Darrell White, MD, Lofti Benboubker, Gordon Cook, MD PhD, Merav Leiba, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, P. Joy Ho, Kihyun Kim, Naoki Takezako, MD PhD, Nushmia Z Khokhar, Mary Guckert, Kaida Wu, MD PhD, Xiang Qin, Tineke Casneuf, Christopher Chiu, PhD, A. Kate Sasser, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1151.

https://doi.org/10.1182/blood.V128.22.1151.1151

Published: 2016

Journal Articles

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Hervé Avet-Loiseau, Tineke Casneuf, Christopher Chiu, PhD, Jacob P. Laubach, MD, Je-Jung Lee, Philippe Moreau, Torben Plesner, Professor, Hareth Nahi, Nushmia Z Khokhar, Ming Qi, Jordan Schecter, Victoria Carlton, PhD, Xiang Qin, Kevin Liu, Kaida Wu, MD PhD, Sen H. Zhuang, MD, PhD, Tahamtan Ahmadi, MD, A. Kate Sasser, PhD, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 246.

https://doi.org/10.1182/blood.V128.22.246.246

Published: 2016

Journal Articles

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Catriona HM Jamieson, MD, PhD, Robert P Hasserjian, MD, Jason Gotlib, MD, MS, Jorge E. Cortes, MD, Richard M. Stone, MD, Moshe Talpaz, MD, Jürgen Thiele, MD, PhD, Scott J Rodig, MD, PhD, Abhay Patki, PhD MBA, Kaida Wu, PhD, MD, Jingyang Wu, MSc, Olga Pozdnyakova, MD, PhD

Blood (2013) 122 (21): 2823.

https://doi.org/10.1182/blood.V122.21.2823.2823

Published: 2013

Journal Articles

A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cdk4/6.

Linda B. Baughn, PhD, Maurizio Di Liberto, PhD, Kaida Wu, PhD, Peter Toogood, PhD, Tracey Louie, Rachel Gottschalk, Ruben Niesvizky, MD, Hearn J. Cho, MD, PhD, Scott Ely, MD, MPH, Malcolm A.S. Moore, D Phil, Selina Chen-Kiang, PhD

Blood (2006) 108 (11): 369.

https://doi.org/10.1182/blood.V108.11.369.369

Published: 2006

Journal Articles

Aberrant Autocrine and Paracrine CD40L Signaling Promotes Primary Myeloma Cell Survival and Attenuates Bortezomib-Induced Apoptosis.

Selina Chen-Kiang, PhD, Scott Ely, MD, MPH, Maurizio Di Liberto, PhD, Kaida Wu, PhD, John Shaughnessy, PhD, Malcolm Moore, DPhil, Ruben Niesvizky, MD, Eunice Hatada, PhD

Blood (2005) 106 (11): 1564.

https://doi.org/10.1182/blood.V106.11.1564.1564

Published: 2005

Journal Articles

The Telomerase Template Antagonist GRN163L in Combination with Chemotherapeutics Reduces Tumor Volume in Multiple Myeloma Xenograft Models.

Server A. Ertem, BS, Kaida Wu, MD, Vladimir Ponomarev, PhD, Allison C. Chin, PhD, Malcolm A.S. Moore, PhD

Blood (2005) 106 (11): 3477.

https://doi.org/10.1182/blood.V106.11.3477.3477

Published: 2005

Journal Articles

Long-Term Coculture of Adult Human Healthy Donor CD34+ Cells Shows Elevation of Telomeres in a Subgroup of Donors Independent of Age, Stem Cell Function and Telomerase Activity.

Katja C. Weisel, M.D., Kaida Wu, M.D., Lothar Kanz, M.D., Malcolm A.S. Moore, D.Phil.

Blood (2004) 104 (11): 1695.

https://doi.org/10.1182/blood.V104.11.1695.1695

Published: 2004

Journal Articles

Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma

Eunice S. Wang, Kaida Wu, Allison C. Chin, Selina Chen-Kiang, Krisztina Pongracz, Sergei Gryaznov, Malcolm A. S. Moore

Blood (2004) 103 (1): 258–266.

https://doi.org/10.1182/blood-2003-02-0546

Published: 2004

Journal Articles

Maintaining the self-renewal and differentiation potential of human CD34 + hematopoietic cells using a single genetic element

James C. Mulloy, Jorg Cammenga, Francisco J. Berguido, Kaida Wu, Ping Zhou, Raymond L. Comenzo, Suresh Jhanwar, Malcolm A. S. Moore, Stephen D. Nimer

Blood (2003) 102 (13): 4369–4376.

https://doi.org/10.1182/blood-2003-05-1762

Published: 2003

NARROW

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cdk4/6.

Aberrant Autocrine and Paracrine CD40L Signaling Promotes Primary Myeloma Cell Survival and Attenuates Bortezomib-Induced Apoptosis.

The Telomerase Template Antagonist GRN163L in Combination with Chemotherapeutics Reduces Tumor Volume in Multiple Myeloma Xenograft Models.

Long-Term Coculture of Adult Human Healthy Donor CD34+ Cells Shows Elevation of Telomeres in a Subgroup of Donors Independent of Age, Stem Cell Function and Telomerase Activity.

Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma

Maintaining the self-renewal and differentiation potential of human CD34 + hematopoietic cells using a single genetic element

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only